KURA · Kura Oncology, Inc.

Kura Oncology Inc KURA

Develops experimental targeted therapies for cancer, including treatments for leukemia.

Industry
Biotechnology
Listed on
Nasdaq NMS
IPO
2015-11-05
Website
kuraoncology.com

Daily brief

Kura Oncology gains after CEO's second stock purchase this month

+9.60% to $13.59 from $12.40

What moved KURA

  • Kura Oncology CEO Troy Wilson purchased 100,000 shares for about $1.24 million, a regulatory filing showed.
  • It was Wilson’s second 100,000-share purchase this month, after buying shares on August 17 at $11.12 each.
  • Shares gained roughly 10-11% following the disclosure.

Sources: Investing.com · GuruFocus · CNBC

More on Kura Oncology, Inc.

Financial history →

← All stocks

This content is for informational purposes only and is not investment advice. Always do your own research before making financial decisions.